Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder

Next Previous
Trial Profile

AXS-05-MDD-301: A Randomized, Double-Blind, Placebo-Controlled Trial of AXS-05 in Subjects With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bupropion/dextromethorphan (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GEMINI
  • Sponsors Axsome Therapeutics

Most Recent Events

  • 29 Oct 2024 According to an Axsome Therapeutics media release, the company presented a Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND) at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts.
  • 11 Dec 2023 Results of pooled post hoc analysis (from studies GEMINI and ASCEND) presented in the Axsome Therapeutics Media Release
  • 07 Sep 2023 According to an Axsome Therapeutics media release, presentations of data at the 2023 U.S. Psych Congress, being held in Nashville, Tenn. from September 6-10.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top